Quarterly ResultAug 13, 2026, 04:19 PM
Equillium Q2 Net Loss $4.7M; Cash Runway into 2029
AI Summary
Equillium reported a net loss of $4.7 million for the second quarter ended June 30, 2026, an improvement from a $5.7 million net loss in the same period of 2025. The company maintained a strong financial position with $57.2 million in cash and cash equivalents, projected to fund operations into 2029. Equillium also highlighted significant clinical progress, including the anticipated initiation of a Phase 1 study for EQ504 in Q4 2026 and the start of IND-enabling development for EQ504 as an inhaled therapy and EQ302 for celiac disease.
Key Highlights
- Net loss for Q2 2026 was $4.7 million, an improvement from $5.7 million in Q2 2025.
- Net loss per share was $(0.04) for Q2 2026, compared to $(0.16) in Q2 2025.
- Cash and cash equivalents totaled $57.2 million as of June 30, 2026.
- Cash runway is expected to fund operations into 2029.
- Research and development expenses decreased to $2.8 million in Q2 2026 from $4.1 million in Q2 2025.
- Phase 1 proof-of-mechanism study for EQ504 expected to initiate in Q4 2026.
- Initiated IND-enabling development activities for EQ504 as a potential inhaled therapy.
- Initiated IND-enabling development activities for EQ302 for celiac disease.
Price Impact
More from EQ